Resource library

Presentations

Videos

Research

Letters & Public Comments

Media

Op-eds & blog posts

Community Quests

Press releases

Presentations

Featured

May 7, 2024

The Impact of the Inflation Reduction Act on Early-Stage Biomedical Investment Decisions

May 7, 2024

Jan 2, 2024

A primer on Generalized Cost-Effectiveness Analysis

Jan 2, 2024

Healthcare Affordability + Innovation

Jan 2, 2024

How public funding, incentives, and private funding function together to enable all of us to get what we want: new medicines

Jan 2, 2024

What’s the big deal about cutting the biggest selling drugs down to just being reasonably profitable?

Jan 2, 2024

How to Kill the Conversation that Makes Innovation Possible

Jan 2, 2024

How Biopharama Innovation… Happens

Jan 2, 2024

The Harmful Consequences of the US Adopting the UK’s Math for Setting Drug Prices

Jan 2, 2024

How the IRA makes new small molecule biotech R&D uninvestable for diseases of aging

Jan 2, 2024

Nov 11, 2023

Beyond total revenues: How the IRA impacts investors’ early-stage R&D decision-making

Nov 11, 2023

Nov 15, 2019

How We Cured Hepatitis C: 15 Years of Ingenuity, Investment, Risk, Failure, and Perseverance

Nov 15, 2019

Videos

Featured

Apr 8, 2025

The Massachusetts Paradox

Apr 8, 2025

Mar 4, 2025

Autoimmune Quest v2: ‘It Takes Grit’

Mar 4, 2025

Autoimmune Quest v1

Mar 4, 2025

Feb 18, 2025

A note of thanks to the FDA

Feb 18, 2025

Feb 15, 2025

Protect American Innovation

Feb 15, 2025

Apr 24, 2024

Don't F*** with the Density of Ice

Apr 24, 2024

Dec 6, 2023

The Investor’s Paradox

Dec 6, 2023

Affordability & Innovation

Dec 6, 2023

Oct 2, 2023

Inventing new medicines is a long climb

Oct 2, 2023

Sep 21, 2022

IRA Webinar: Impact of the Inflation Reduction Act for Biotech Builders… and (how) can it be fixed?

Sep 21, 2022

Jan 5, 2022

What is Abbie Saving For?

Jan 5, 2022

Nov 18, 2021

The Failure to Communicate Value

Nov 18, 2021

Nov 1, 2020

The Value of Medicines

Nov 1, 2020

Research

Featured

Mar 12, 2025

Price Controls Hinder Treatment Access in Medicare Part D

Mar 12, 2025

Feb 12, 2025

Consumers sound alarm: state price controls will limit access without lowering patient costs

Feb 12, 2025

Nov 27, 2024

Estimating a Drug’s Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold

Nov 27, 2024

Nov 8, 2024

NEW REPORT: Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices

Nov 8, 2024

Mar 8, 2024

Value in Health: It’s time to reconsider the three percent discount rate.

Mar 8, 2024

Jan 30, 2024

Is the price right? Paying for value today to get more value tomorrow

Jan 30, 2024

Jan 2, 2024

When simpler isn’t better: a case for generalized cost-effectiveness analysis

Jan 2, 2024

Why the discount rate is exciting!

Jan 2, 2024

Dec 5, 2023

The American Journal of Managed Care: Generalized Cost-Effectiveness Analysis to Assess Treatment Value in Hepatitis C

Dec 5, 2023

Sep 26, 2023

Getting the math right when measuring the value of new medicines

Sep 26, 2023

Nov 18, 2021

Do Cost-Effectiveness Analyses Account for Drug Genericization?

Nov 18, 2021

Letters & Public Comments

Featured

Apr 4, 2025

A Letter to Senate HELP Committee Chairman Bill Cassidy on Preserving and Modernizing the FDA

Apr 4, 2025

Mar 11, 2025

Public Comment: End Unfair Trade Practices in Drug Pricing

Mar 11, 2025

Feb 18, 2025

Public Comment: Use tariff and market access tools to force OECD countries to pay their fair share for medical innovation

Feb 18, 2025

Feb 10, 2025

Open letter to President Trump from biopharma innovators, investors, and patient advocates regarding proposed FDA budget and personnel cuts.

Feb 10, 2025

Feb 6, 2025

Defending the NIH, the NSF, and the foundation of American science

Feb 6, 2025

Jan 27, 2025

Public Comment: Allow Medicare to cover anti-obesity medications (AOMs) and strengthen patient protection “guardrails” through better oversight of Medicare Advantage Part D (MAPD) plans.

Jan 27, 2025

Jul 2, 2024

Public Comment: Share savings from Medicare price setting with patients not plans

Jul 2, 2024

Jan 17, 2024

NEW LETTER: Investors and executives urge the Congressional Budget Office to adopt changes to its modeling

Jan 17, 2024

Aug 18, 2023

Sign-on letter: Why Fixing the IRA Matters to all of us

Aug 18, 2023

Apr 14, 2023

Public Comment: Protect patients when implementing the price setting provisions of the Inflation Reduction Act

Apr 14, 2023

Apr 8, 2023

Mifepristone ruling: biotech leaders defend FDA's autonomy and authority

Apr 8, 2023

Mar 27, 2023

Public Comment: Exemptions of the Inflation Reduction Act fail to provide adequate protections

Mar 27, 2023

Jul 25, 2022

An investor analysis of the Inflation Reduction Act: What the bill will mean for future cures

Jul 25, 2022

Do more for patients, preserve innovation: Fix the Inflation Reduction Act

Jul 25, 2022

Media

Featured

Mar 4, 2025

Autoimmune Quest v2: ‘It Takes Grit’

Mar 4, 2025

Autoimmune Quest v1

Mar 4, 2025

Nov 26, 2024

Journal of Comparative Effectiveness Research: Generalized cost–effectiveness analysis - charting a path forward for measuring the societal value of medical technologies

Nov 26, 2024

Nov 13, 2024

The Evidence Base: New framework proposed for valuing medicines’ broader societal impact

Nov 13, 2024

Oct 25, 2024

R&D World: How much does the pharma industry spend on R&D anyway? Probably more than you thought

Oct 25, 2024

Oct 1, 2024

USA Today: Mammograms can prevent breast cancer deaths. But many skip screening due to cost.

Oct 1, 2024

Aug 10, 2024

Cambridge Day: Health care costs keep rising, but biopharma is not the enemy

Aug 10, 2024

Jul 10, 2024

AI can make it easier to discover new medicines – but Congress is making it harder

Jul 10, 2024

May 6, 2024

STAT News: The world is relying on the United States to get value-based drug pricing right

May 6, 2024

Mar 5, 2024

5 ways Biden’s SOTU could advance biotech affordability and innovation

Mar 5, 2024

Dec 14, 2023

Bucks County Herald: Drug price controls hurt investment in new medicines

Dec 14, 2023

Nov 30, 2023

Fairfax Connection: Our Neighborhood’s Special Role in Saving Babies from Norovirus

Nov 30, 2023

Nov 1, 2023

The Well News: Ensuring Medicare Rx Price Negotiations Help Patients

Nov 1, 2023

Oct 2, 2023

Xtelligent Healthcare: The Importance of Accurately Measuring the Value of New Medications

Oct 2, 2023

Op-eds and blog posts

Featured

Nov 26, 2024

Journal of Comparative Effectiveness Research: Generalized cost–effectiveness analysis - charting a path forward for measuring the societal value of medical technologies

Nov 26, 2024

May 6, 2024

STAT News: The world is relying on the United States to get value-based drug pricing right

May 6, 2024

Mar 5, 2024

5 ways Biden’s SOTU could advance biotech affordability and innovation

Mar 5, 2024

Nov 1, 2023

The Well News: Ensuring Medicare Rx Price Negotiations Help Patients

Nov 1, 2023

Mar 31, 2023

Measuring the damage: IRA’s impact on small molecule drug development

Mar 31, 2023

Aug 2, 2022

The Well News: Misguided Rating Cancels Rare Disease Patients

Aug 2, 2022

Feb 18, 2022

RealClearHealth: For Two Years, Australia Failed People With Cystic Fibrosis; It Can’t Happen Again

Feb 18, 2022

Jan 4, 2022

The Well News: Fix BBB’s Rx Provisions so Patients Aren’t Stuck With High Bills and More Needles

Jan 4, 2022

May 12, 2021

Timmerman Report: Aducanumab & the Alzheimer’s Moonshot: What Would It Be Worth to Keep Your Mind?

May 12, 2021

Dec 25, 2020

PBMs: The Secretive Middlemen for Insurance and Drug Companies

Dec 25, 2020

Community Quests

Featured

Mar 4, 2025

Autoimmune Quest v2: ‘It Takes Grit’

Mar 4, 2025

Autoimmune Quest v1

Mar 4, 2025

Aug 10, 2024

Cambridge Day: Health care costs keep rising, but biopharma is not the enemy

Aug 10, 2024

Jul 10, 2024

AI can make it easier to discover new medicines – but Congress is making it harder

Jul 10, 2024

Dec 14, 2023

Bucks County Herald: Drug price controls hurt investment in new medicines

Dec 14, 2023

Nov 30, 2023

Fairfax Connection: Our Neighborhood’s Special Role in Saving Babies from Norovirus

Nov 30, 2023

Press Releases

Featured

Mar 12, 2025

New Study Highlights Challenges in Medicare Part D Treatment Access and Major Concerns over Inflation Reduction Act

Mar 12, 2025

Feb 12, 2025

New Study Reveals Widespread Concern over Prescription Price Controls, Costs, and Access

Feb 12, 2025

Dec 12, 2024

NPLB Statement on Murder of Brian Thompson

Dec 12, 2024

Nov 11, 2024

New Paper: Leading Health Economists Explain How to Fix the Faulty & Outdated Models Used to Calculate the Value of Medicines

Nov 11, 2024

May 3, 2024

Getting the Math Right: The Growing Movement to Improve How Medicines Are Valued Will Take Center Stage at ISPOR 2024

May 3, 2024

Apr 1, 2024

APRIL FOOLS’: FTC Announces Zero Copay Mandate

Apr 1, 2024

Jan 30, 2024

Investors and Innovators Representing more than $309B in Biotech Assets and 624 New Drugs in Development Urge the Congressional Budget Office to Update its Drug R&D Policy Impact Model

Jan 30, 2024

Sep 25, 2023

Statement / Background Info Regarding the Institute for Clinical and Economic Review’s (ICER) Proposed Value Assessment Framework

Sep 25, 2023

Sep 6, 2023

Innovative Medicines Provide Greater Value to Patients and Society than Previously Calculated

Sep 6, 2023

Jun 30, 2023

NPLB Statement on ICER’s Flawed Value Assessment Framework

Jun 30, 2023

Dec 8, 2022

New NPLB Video Illustrates Why Patients Deserve Better Math to Value New Drugs

Dec 8, 2022

Aug 18, 2022

NPLB Gets Animated: Roadmap to Patient Affordability and Innovation

Aug 18, 2022

Jul 25, 2022

One Thousand Investors, Researchers, Patients, & Innovators Sign Letter Urging Critical Fixes to Senate Rx Bill

Jul 25, 2022

Jan 10, 2022

“Abbie” Video Highlights Need for Insurance Reforms that Lower Out-of-Pocket Costs

Jan 10, 2022

We’re building support across the biotech ecosystem

BECOME A FIRST RESPONDER & THOUGHT PARTNER

Sign up to receive action alerts. Help protect access to lifesaving medicines & preserve innovation for those still waiting for a cure.